ArticleFrontiers in endocrinology2026
Predicting heart failure in asymptomatic diabetes: derivation and internal validation of a clinical prediction model for early detection of diabetic cardiomyopathy.
Article in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To develop and internally validate a clinical prediction model for identifying asymptomatic type 2 diabetes (T2DM) patients at risk of incident heart failure (HF) or progression of subclinical cardiac dysfunction. Methods: This single-center retrospective study included 326 asymptomatic T2DM patients with preserved LVEF, all with ≥3 echocardiographic assessments over 24 months. The primary outcome was a composite of incident clinical HF (classified as HFpEF or HFrEF based on symptoms, hospitalization, natriuretic peptides, and follow-up echo) and imaging-defined progression of subclinical dysfunction. Candidate predictors (clinical variables, GLS, LASr, E/e', LAVI, LVMI, NT-proBNP, galectin-3) were pre-specified. Missing data were handled by multiple imputation. A risk score was derived using multivariable Cox regression with Fine-Gray competing risk analysis, and optimism was assessed via bootstrap, 5-fold cross-validation, and internal split-sample validation. Results: Over 24 months, LV GLS modestly declined (17.4 ± 2.0% to 16.9 ± 2.1%), while LASr deteriorated more (38.5 ± 7.2% to 34.0 ± 6.5%). Independent predictors of the composite outcome were LASr ≤24% (HR 3.58), NT-proBNP ≥120 pg/mL (HR 2.48), galectin-3 ≥15 ng/mL (HR 1.79), age ≥70 years, diabetes duration ≥12 years, BMI ≥30 kg/m², and UACR ≥60 mg/g; SGLT2i/GLP-1 RA use was associated with lower observed risk. During follow-up, 40 patients reached the composite outcome (18 clinical HF: 14 HFpEF, 4 HFrEF; 22 imaging-only progression). The scoring system stratified patients into low- (≤3 points), intermediate- (4-6), and high-risk (≥7) groups, with 24-month cumulative incidences of 4.2%, 11.7%, and 27.5% (Gray's test P<0.001). The full model had a C-statistic of 0.835 (bootstrap-corrected 0.828) and good calibration (Brier score 0.068). Adding LASr and galectin-3 improved discrimination (ΔC=0.058 and 0.012, both P<0.05). Conclusion: Integrating LASr, galectin-3, and clinical risk factors may help identify asymptomatic T2DM patients at higher risk of incident HF or subclinical progression. This internally validated model may support preliminary risk stratification for suspected early diabetic cardiomyopathy, but external validation and clinical utility assessment are needed before routine use.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.